Skip to main content
Erschienen in: CNS Drugs 8/2018

01.08.2018 | Original Research Article

The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsing–Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study

verfasst von: Robert Zivadinov, Eleonora Tavazzi, Jesper Hagemeier, Ellen Carl, David Hojnacki, Channa Kolb, Bianca Weinstock-Guttman

Erschienen in: CNS Drugs | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Optical coherence tomography (OCT) is a technique that allows for the assessment of retinal nerve fiber layer thickness (RNFLT) and total macular volume (TMV), which reflect neuroaxonal integrity within the retina. As such it has been used in multiple sclerosis (MS) to study neurodegeneration. Glatiramer acetate (GA) is a widely used treatment for MS, which is suggested to have a possible neuroprotective role.

Objective

The aim of this study was to assess RFNLT and TMV changes in relapsing–remitting MS (RRMS) patients who started treatment with GA and were followed for a 24-month period.

Methods

A cohort of 60 RRMS patients and 40 healthy controls (HCs) were imaged with OCT at baseline and follow-up. All subjects also underwent clinical and neurological examination. Measurements were compared between the RRMS patients and HCs as well as between optic neuritis (ON)-affected and ON-unaffected eyes.

Results

At baseline, MS patients showed lower average RNFLT (p = 0.046) and TMV (p = 0.013) when compared with HCs. No significant differences in the evolution of OCT measures were detected over the follow-up between MS patients and HCs. MS patients with both affected and unaffected eyes showed significantly lower average RNFLT, temporal inferior RNFLT, and TMV at baseline, compared with HCs. No significant differences between ON-affected and ON-unaffected eyes in MS patients were detected over the follow-up, except for the nasal superior RNFLT (p = 0.019).

Conclusions

This study suggests a beneficial role of GA on retinal axonal degeneration in MS, and further confirms the utility of OCT to monitor the neuroprotective effect of disease-modifying treatment.
Literatur
1.
Zurück zum Zitat Zivadinov R, et al. Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Rev Neurother. 2016;16(7):777–93.CrossRef Zivadinov R, et al. Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Rev Neurother. 2016;16(7):777–93.CrossRef
2.
Zurück zum Zitat Johnson KP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268–76.CrossRef Johnson KP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268–76.CrossRef
3.
Zurück zum Zitat Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol. 2001;49(3):290–7.CrossRef Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol. 2001;49(3):290–7.CrossRef
4.
Zurück zum Zitat Khan O, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013;73(6):705–13.CrossRef Khan O, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013;73(6):705–13.CrossRef
5.
Zurück zum Zitat Arnold DL, Narayanan S, Antel S. Neuroprotection with glatiramer acetate: evidence from the PreCISe trial. J Neurol. 2013;260(7):1901–6.CrossRef Arnold DL, Narayanan S, Antel S. Neuroprotection with glatiramer acetate: evidence from the PreCISe trial. J Neurol. 2013;260(7):1901–6.CrossRef
6.
Zurück zum Zitat Zivadinov R, et al. Glatiramer acetate recovers microscopic tissue damage in patients with multiple sclerosis. A case-control diffusion imaging study. Pathophysiology. 2011;18(1):61–8.CrossRef Zivadinov R, et al. Glatiramer acetate recovers microscopic tissue damage in patients with multiple sclerosis. A case-control diffusion imaging study. Pathophysiology. 2011;18(1):61–8.CrossRef
7.
Zurück zum Zitat Khan O, et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler. 2005;11(6):646–51.CrossRef Khan O, et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler. 2005;11(6):646–51.CrossRef
8.
Zurück zum Zitat Balk LJ, et al. Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study. J Neurol. 2016;263(7):1323–31.CrossRef Balk LJ, et al. Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study. J Neurol. 2016;263(7):1323–31.CrossRef
9.
Zurück zum Zitat Brandt AU, et al. Monitoring the course of MS with optical coherence tomography. Curr Treat Options Neurol. 2017;19(4):15.CrossRef Brandt AU, et al. Monitoring the course of MS with optical coherence tomography. Curr Treat Options Neurol. 2017;19(4):15.CrossRef
10.
Zurück zum Zitat Grazioli E, et al. Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. J Neurol Sci. 2008;268(1–2):12–7.CrossRef Grazioli E, et al. Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. J Neurol Sci. 2008;268(1–2):12–7.CrossRef
11.
Zurück zum Zitat Gupta S, et al. Optical coherence tomography and neurodegeneration: are eyes the windows to the brain? Expert Rev Neurother. 2016;16(7):765–75.CrossRef Gupta S, et al. Optical coherence tomography and neurodegeneration: are eyes the windows to the brain? Expert Rev Neurother. 2016;16(7):765–75.CrossRef
12.
Zurück zum Zitat Button J, et al. Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: a retrospective study. Neurology. 2017;88(6):525–32.CrossRef Button J, et al. Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: a retrospective study. Neurology. 2017;88(6):525–32.CrossRef
13.
Zurück zum Zitat Polman CH, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302.CrossRef Polman CH, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302.CrossRef
14.
Zurück zum Zitat Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907–11.CrossRef Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907–11.CrossRef
15.
Zurück zum Zitat Zivadinov R, et al. Cerebral microbleeds in multiple sclerosis evaluated on susceptibility-weighted images and quantitative susceptibility maps: a case–control study. Radiology. 2016;281(3):884–95.CrossRef Zivadinov R, et al. Cerebral microbleeds in multiple sclerosis evaluated on susceptibility-weighted images and quantitative susceptibility maps: a case–control study. Radiology. 2016;281(3):884–95.CrossRef
16.
Zurück zum Zitat Tewarie P, et al. The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS One. 2012;7(4):e34823.CrossRef Tewarie P, et al. The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS One. 2012;7(4):e34823.CrossRef
17.
Zurück zum Zitat Zivadinov R, et al. Retinal nerve fiber layer thickness and thalamus pathology in multiple sclerosis patients. Eur J Neurol. 2014;21(8):1137-e61.CrossRef Zivadinov R, et al. Retinal nerve fiber layer thickness and thalamus pathology in multiple sclerosis patients. Eur J Neurol. 2014;21(8):1137-e61.CrossRef
18.
Zurück zum Zitat Syc SB, et al. Reproducibility of high-resolution optical coherence tomography in multiple sclerosis. Mult Scler. 2010;16(7):829–39.CrossRef Syc SB, et al. Reproducibility of high-resolution optical coherence tomography in multiple sclerosis. Mult Scler. 2010;16(7):829–39.CrossRef
19.
Zurück zum Zitat West B, Welch K, Galecki A. A practical guide using statistical software. London: Chapman & Hall/CRC; 2006. ISBN 978-1-584-88480-4. West B, Welch K, Galecki A. A practical guide using statistical software. London: Chapman & Hall/CRC; 2006. ISBN 978-1-584-88480-4.
20.
Zurück zum Zitat Behbehani R, et al. Optical coherence tomography segmentation analysis in relapsing remitting versus progressive multiple sclerosis. PLoS One. 2017;12(2):e0172120.CrossRef Behbehani R, et al. Optical coherence tomography segmentation analysis in relapsing remitting versus progressive multiple sclerosis. PLoS One. 2017;12(2):e0172120.CrossRef
21.
Zurück zum Zitat Garcia-Martin E, et al. Risk factors for progressive axonal degeneration of the retinal nerve fibre layer in multiple sclerosis patients. Br J Ophthalmol. 2011;95(11):1577–82.CrossRef Garcia-Martin E, et al. Risk factors for progressive axonal degeneration of the retinal nerve fibre layer in multiple sclerosis patients. Br J Ophthalmol. 2011;95(11):1577–82.CrossRef
22.
Zurück zum Zitat El Ayoubi NK, et al. Retinal measures correlate with cognitive and physical disability in early multiple sclerosis. J Neurol. 2016;263(11):2287–95.CrossRef El Ayoubi NK, et al. Retinal measures correlate with cognitive and physical disability in early multiple sclerosis. J Neurol. 2016;263(11):2287–95.CrossRef
23.
Zurück zum Zitat Green AJ, et al. Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. Brain. 2010;133(Pt 6):1591–601.CrossRef Green AJ, et al. Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. Brain. 2010;133(Pt 6):1591–601.CrossRef
24.
Zurück zum Zitat Reich DS, et al. Damage to the optic radiation in multiple sclerosis is associated with retinal injury and visual disability. Arch Neurol. 2009;66(8):998–1006.CrossRef Reich DS, et al. Damage to the optic radiation in multiple sclerosis is associated with retinal injury and visual disability. Arch Neurol. 2009;66(8):998–1006.CrossRef
25.
Zurück zum Zitat Ratchford JN, et al. Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology. 2013;80(1):47–54.CrossRef Ratchford JN, et al. Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology. 2013;80(1):47–54.CrossRef
26.
Zurück zum Zitat Aharoni R. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmun Rev. 2013;12(5):543–53.CrossRef Aharoni R. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmun Rev. 2013;12(5):543–53.CrossRef
27.
Zurück zum Zitat Spadaro M, et al. Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10 years in responder multiple sclerosis patients. Clin Immunol. 2017;181:83–8.CrossRef Spadaro M, et al. Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10 years in responder multiple sclerosis patients. Clin Immunol. 2017;181:83–8.CrossRef
28.
Zurück zum Zitat Arnon R, Aharoni R. Neurogenesis and neuroprotection in the CNS–fundamental elements in the effect of Glatiramer acetate on treatment of autoimmune neurological disorders. Mol Neurobiol. 2007;36(3):245–53.CrossRef Arnon R, Aharoni R. Neurogenesis and neuroprotection in the CNS–fundamental elements in the effect of Glatiramer acetate on treatment of autoimmune neurological disorders. Mol Neurobiol. 2007;36(3):245–53.CrossRef
29.
Zurück zum Zitat Toledo J, et al. Retinal nerve fiber layer atrophy is associated with physical and cognitive disability in multiple sclerosis. Mult Scler. 2008;14(7):906–12.CrossRef Toledo J, et al. Retinal nerve fiber layer atrophy is associated with physical and cognitive disability in multiple sclerosis. Mult Scler. 2008;14(7):906–12.CrossRef
30.
Zurück zum Zitat Gordon-Lipkin E, et al. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology. 2007;69(16):1603–9.CrossRef Gordon-Lipkin E, et al. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology. 2007;69(16):1603–9.CrossRef
31.
Zurück zum Zitat Filippi M, Preziosa P, Rocca MA. Microstructural MR imaging techniques in multiple sclerosis. Neuroimaging Clin N Am. 2017;27(2):313–33.CrossRef Filippi M, Preziosa P, Rocca MA. Microstructural MR imaging techniques in multiple sclerosis. Neuroimaging Clin N Am. 2017;27(2):313–33.CrossRef
32.
Zurück zum Zitat Barkhof F. MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). Mult Scler. 1999;5(4):283–6.CrossRef Barkhof F. MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). Mult Scler. 1999;5(4):283–6.CrossRef
33.
Zurück zum Zitat Hackmack K, et al. Can we overcome the ‘clinico-radiological paradox’ in multiple sclerosis? J Neurol. 2012;259(10):2151–60.CrossRef Hackmack K, et al. Can we overcome the ‘clinico-radiological paradox’ in multiple sclerosis? J Neurol. 2012;259(10):2151–60.CrossRef
34.
Zurück zum Zitat Saidha S, et al. Optical coherence tomography reflects brain atrophy in multiple sclerosis: a four-year study. Ann Neurol. 2015;78(5):801–13.CrossRef Saidha S, et al. Optical coherence tomography reflects brain atrophy in multiple sclerosis: a four-year study. Ann Neurol. 2015;78(5):801–13.CrossRef
35.
Zurück zum Zitat Pisa M, et al. No evidence of disease activity is associated with reduced rate of axonal retinal atrophy in MS. Neurology. 2017;89:2469–75.CrossRef Pisa M, et al. No evidence of disease activity is associated with reduced rate of axonal retinal atrophy in MS. Neurology. 2017;89:2469–75.CrossRef
36.
Zurück zum Zitat Garcia-Martin E, et al. Effect of optic neuritis on progressive axonal damage in multiple sclerosis patients. Mult Scler. 2011;17(7):830–7.CrossRef Garcia-Martin E, et al. Effect of optic neuritis on progressive axonal damage in multiple sclerosis patients. Mult Scler. 2011;17(7):830–7.CrossRef
37.
Zurück zum Zitat Petzold A, et al. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2017;16(10):797–812.CrossRef Petzold A, et al. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2017;16(10):797–812.CrossRef
38.
Zurück zum Zitat Cruz-Herranz A, et al. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology. 2016;86(24):2303–9.CrossRef Cruz-Herranz A, et al. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology. 2016;86(24):2303–9.CrossRef
Metadaten
Titel
The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsing–Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study
verfasst von
Robert Zivadinov
Eleonora Tavazzi
Jesper Hagemeier
Ellen Carl
David Hojnacki
Channa Kolb
Bianca Weinstock-Guttman
Publikationsdatum
01.08.2018
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 8/2018
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-018-0521-9

Weitere Artikel der Ausgabe 8/2018

CNS Drugs 8/2018 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.